The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Upadacitinib Safety Similar to Other Jakinibs for RA

Upadacitinib Safety Similar to Other Jakinibs for RA

November 16, 2020 • By Lisa Rapaport

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters Health)—A once-daily 15 mg dose of upadacitinib for rheumatoid arthritis (RA) has similar rates of malignancies, serious infections, major adverse cardiovascular events, and venous thromboembolic events as other Janus kinase inhibitors (jakinibs), results from phase 3 clinical trials suggest.

You Might Also Like
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Promising for RA Patients
  • Upadacitinib Meets Study Endpoints to Treat RA

Researchers examined data on treatment emergent adverse events among patients taking upadacitinib in five randomized phase 3 clinical trials with either placebo or active controls. Across all the trials, a total of 3,834 patients took one or more doses of upadacitinib: 15 mg (n=2,630) or 30 mg (n=1,204) for a total of 4,020.1 person-years of exposure to the drug.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The 15 mg dose of upadacitinib had higher risk of herpes zoster than methotrexate (hazard ratio [HR] 2.997) and adalimumab (HR 3.211). This dose also had a higher risk of creatine phosphokinase elevations than placebo (HR 2.314), methotrexate (HR 2.701) and adalimumab (HR 2.588).

Meanwhile, the 30 mg dose of upadacitinib had a higher risk of herpes zoster and creatine phosphokinase elevations than placebo (HR 4.427 and 2.679, respectively), methotrexate (HR 3.023 and 5.578, respectively) and adalimumab (HR 4.989 and 3.073, respectively). This higher upadacitinib dose also had a greater risk of serious infections than placebo (HR 3.243) and adalimumab (HR 1.927).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Based on the phase 3 development program and the long-term extension studies this clearly demonstrates that the benefit of upadacitinib outweighs the risk,” says lead study author Stanley Cohen, MD, medical director of the Metroplex Clinical Research Center and a clinical professor at the University of Texas Southwestern Medical School, Dallas.

“Upadacitinib demonstrated significant efficacy in early rheumatoid arthritis, methotrexate incomplete responders and biologic incomplete responders,” Dr. Cohen says by email. “The safety profile other than the zoster signal is similar to what we see with biologics, and the [jakinibs] represent an oral alternative to the biologics which require injections.”

Across all the trials in the analysis, patients had been diagnosed with rheumatoid arthritis for a median of 1.2 to 6.4 years and received one or more doses of upadacitinib for a mean duration of about 1 year. The longest exposure to upadacitinib was 2.5 years; 66% of participants received the drug for at least 48 weeks and 4% took the drug for at least 96 weeks.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

One limitation of the study is that researchers lacked long-term placebo data to compare with long-term use of upadacitinib, the study team notes. The study also looked at monotherapy, and researchers lacked data on long-term safety for combination therapy involving upadacitinib, they note in Annals of the Rheumatic Diseases.1

Pages: 1 2 | Single Page

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: JAK inhibitors, jakinib, Rheumatoid Arthritis (RA), upadacitinib

You Might Also Like:
  • Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
  • Upadacitinib Promising for RA Patients
  • Upadacitinib Meets Study Endpoints to Treat RA
  • Upadacitinib Promising for RA in Phase 3 Study

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)